(Q33421729)

26 July 2017

1 reference

title

Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus (English)

1 reference

26 July 2017

1 reference

L J Scott

1

1 reference

PubMed ID

10776834

26 July 2017

C M Spencer

series ordinal

2

1 reference

26 July 2017

1 March 2000

1 reference

26 July 2017

1 reference

26 July 2017

59

1 reference

26 July 2017

521-549

1 reference

26 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200059030-00012

26 July 2017

0 references

cites work

The effects of improved glycemic control on complications in type 2 diabetes

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059030-00012

Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059030-00012

Postprandial hyperglycaemia and alpha-glucosidase inhibitors.

21 January 2018

1 reference

12 December 2020

The effect of new alpha-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man.

1 reference

12 December 2020

The roles of alpha-glucosidase inhibitors in diabetes

1 reference

12 December 2020

Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study.

1 reference

12 December 2020

Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus

1 reference

12 December 2020

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

12 December 2020

1 reference

12 December 2020

The role of blood glucose-lowering drugs in the light of the UKPDS. United Kingdom Prospective Diabetes Study

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Is type II diabetes mellitus a disease of the innate immune system?

1 reference

12 December 2020

Alpha glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.

1 reference

12 December 2020

Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II)

1 reference

12 December 2020

The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease.

1 reference

12 December 2020

Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man.

1 reference

12 December 2020

Recent developments and emerging therapies for type 2 diabetes mellitus

1 reference

12 December 2020

Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients

1 reference

12 December 2020

Type 2 diabetes: glycemic targets and oral therapies for older patients.

1 reference

12 December 2020

The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results

1 reference

12 December 2020

Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro.

1 reference

12 December 2020

The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics

1 reference

12 December 2020

Intestinal and metabolic responses to an alpha-glucosidase inhibitor in normal volunteers.

1 reference

12 December 2020

Inhibition of Glycemic and Hormonal Responses after Repetitive Sucrose and Starch Loads by Different Doses of the &alpha;-Glucosidase Inhibitor Miglitol (BAY m 1099) in Man

1 reference

12 December 2020

Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine

1 reference

12 December 2020

Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition

1 reference

12 December 2020

Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results

1 reference

12 December 2020

Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans

1 reference

12 December 2020

Pharmacological strategies to prevent macrovascular disease in NIDDM

1 reference

12 December 2020

The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?

1 reference

12 December 2020

Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral- and acid alpha-glucosidases in human fibroblasts and HepG2 cells

1 reference

12 December 2020

Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients

1 reference

12 December 2020

Miglitol may have a blood glucose lowering effect unrelated to inhibition of alpha-glucosidase.

1 reference

12 December 2020

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

1 reference

12 December 2020

Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.

1 reference

12 December 2020

Effect of the alpha-glucosidase inhibitor N-hydroxyethyl-1-deoxynojirimycin (Bay m 1099) on the biosynthesis of liver secretory glycoproteins

1 reference

12 December 2020

Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

1 reference

12 December 2020

Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes

1 reference

12 December 2020

Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors

1 reference

12 December 2020

Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment

1 reference

12 December 2020

Pharmacology of alpha-glucosidase inhibition.

1 reference

12 December 2020

Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the alpha-glucosidase inhibitor miglitol

1 reference

12 December 2020

Oral antidiabetic drug use in the elderly

1 reference

12 December 2020

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

1 reference

12 December 2020

Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes? Need for trial evidence

1 reference

12 December 2020

Cardiovascular risk in type 2 diabetes

1 reference

12 December 2020

Antihyperglycaemic agents. Drug interactions of clinical importance

1 reference

12 December 2020

Drug therapy of postprandial hyperglycaemia.

1 reference

12 December 2020

Preventing long term complications. Implications for combination therapy with acarbose

1 reference

12 December 2020

Diabetes mellitus in older patients. Is tight blood glucose control warranted?

1 reference

12 December 2020

Management of non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?

1 reference

12 December 2020

Management of Non-Insulin-Dependent Diabetes Mellitus

1 reference

12 December 2020

Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients.

1 reference

12 December 2020

The postprandial state and risk of cardiovascular disease

1 reference

12 December 2020

An evaluation of the potential side-effects of alpha-glucosidase inhibitors used for the management of diabetes mellitus.

1 reference

12 December 2020

Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males

1 reference

12 December 2020

alpha-Glucosidase inhibition by miglitol in NIDDM patients

1 reference

12 December 2020

The United Kingdom Prospective Diabetes Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus

1 reference

12 December 2020

Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients

1 reference

12 December 2020

Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers.

1 reference

12 December 2020

A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics

1 reference

12 December 2020

Drug therapy of non-insulin-dependent diabetes mellitus in the elderly

1 reference

12 December 2020

Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses

1 reference

12 December 2020

Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients

1 reference

12 December 2020

New oral agents for type II diabetes. Taking a more aggressive approach to therapy

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic relationships of Acarbose

1 reference

12 December 2020

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

1 reference

12 December 2020

NIDDM and its metabolic control predict coronary heart disease in elderly subjects

1 reference

12 December 2020

10.2165/00003495-200059030-00012

Identifiers

DOI

1 reference

PubMed ID

10776834

Dimensions Publication ID

26 July 2017

0 references

1 reference

PubMed ID

10776834